Gone quiet · last update Oct 7, 2026 / Texas

The fight over the abortion pill: mifepristone access and doctors who mail it

Overview · reviewed October 28, 2026

Mifepristone, one of the two drugs used in medication abortion, the most common method of abortion in the US, has been at the center of a legal and political fight in the years since the Supreme Court overturned the nationwide right to abortion.[1][2][3] The Supreme Court rejected a challenge to the drug's approval in 2024 and in May 2026 kept access by telemedicine and mail in place after an appeals court blocked it.[3][4] States with abortion bans are now pursuing doctors in shield-law states who mail the pills, and in the fall of 2026 three of them asked the Supreme Court to strike down those shield laws.[5][6][7] The Food and Drug Administration says its own safety review of the drug will continue into 2027.[8]

Read the timeline

Follow this story to see new developments when you return.

The Supreme Court rejected a challenge to the drug's approval in 2024 and in May 2026 kept access by telemedicine and mail in place after an appeals court blocked it.[3][4] States with abortion bans are now pursuing doctors in shield-law states who mail the pills, and in the fall of 2026 three of them asked the Supreme Court to strike down those shield laws.[5][6][7] The Food and Drug Administration says its own safety review of the drug will continue into 2027.[8]

Coverage over time

Share of tracked outlets · monthly average of weekly shares (UTC)

Nov 2021: average weekly share 2% (left under 1%, center 1%, right 0%), from 1 of 1 weekDec 2021: average weekly share 5% (left 1%, center 3%, right 1%), from 4 of 4 weeksJan 2022: average weekly share 0% (left 0%, center 0%, right 0%), from 5 of 5 weeksFeb 2022: average weekly share 1% (left under 1%, center 1%, right 0%), from 4 of 4 weeksMar 2022: average weekly share 0% (left 0%, center 0%, right 0%), from 4 of 4 weeksApr 2022: average weekly share 0% (left 0%, center 0%, right 0%), from 4 of 4 weeksMay 2022: average weekly share 0% (left 0%, center 0%, right 0%), from 5 of 5 weeksJun 2022: average weekly share 0% (left 0%, center 0%, right 0%), from 4 of 4 weeksJul 2022: average weekly share 0% (left 0%, center 0%, right 0%), from 4 of 4 weeksAug 2022: average weekly share 0% (left 0%, center 0%, right 0%), from 5 of 5 weeksSep 2022: average weekly share 0% (left 0%, center 0%, right 0%), from 4 of 4 weeksOct 2022: average weekly share 0% (left 0%, center 0%, right 0%), from 5 of 5 weeksNov 2022: average weekly share 1% (left under 1%, center under 1%, right 1%), from 4 of 4 weeksDec 2022: average weekly share 0% (left 0%, center 0%, right 0%), from 4 of 4 weeksJan 2023: average weekly share 7% (left 2%, center 3%, right 2%), from 5 of 5 weeksFeb 2023: average weekly share 4% (left 1%, center 2%, right 1%), from 4 of 4 weeksMar 2023: average weekly share 7% (left 2%, center 3%, right 1%), from 4 of 4 weeksApr 2023: average weekly share 32% (left 13%, center 13%, right 6%), from 4 of 4 weeksMay 2023: average weekly share 1% (left under 1%, center under 1%, right under 1%), from 5 of 5 weeksJun 2023: average weekly share 0% (left 0%, center 0%, right 0%), from 4 of 4 weeksJul 2023: average weekly share 0% (left 0%, center 0%, right 0%), from 5 of 5 weeksAug 2023: average weekly share 5% (left 2%, center 2%, right 2%), from 4 of 4 weeksSep 2023: average weekly share 2% (left 1%, center 1%, right under 1%), from 4 of 4 weeksOct 2023: average weekly share 0% (left 0%, center 0%, right 0%), from 5 of 5 weeksNov 2023: average weekly share 0% (left 0%, center 0%, right 0%), from 4 of 4 weeksDec 2023: average weekly share 8% (left 3%, center 3%, right 2%), from 4 of 4 weeksJan 2024: average weekly share 1% (left under 1%, center under 1%, right under 1%), from 5 of 5 weeksFeb 2024: average weekly share 5% (left 2%, center 2%, right 1%), from 4 of 4 weeksMar 2024: average weekly share 11% (left 4%, center 5%, right 2%), from 4 of 4 weeksApr 2024: average weekly share 1% (left 0%, center under 1%, right under 1%), from 5 of 5 weeksMay 2024: average weekly share 7% (left 2%, center 3%, right 2%), from 4 of 4 weeksJun 2024: average weekly share 11% (left 5%, center 4%, right 2%), from 4 of 4 weeksJul 2024: average weekly share 0% (left 0%, center 0%, right 0%), from 5 of 5 weeksAug 2024: average weekly share 0% (left 0%, center 0%, right 0%), from 4 of 4 weeksSep 2024: average weekly share 1% (left under 1%, center 1%, right under 1%), from 5 of 5 weeksOct 2024: average weekly share 0% (left 0%, center 0%, right 0%), from 4 of 4 weeksNov 2024: average weekly share 1% (left under 1%, center under 1%, right 1%), from 4 of 4 weeksDec 2024: average weekly share 3% (left 1%, center 1%, right 1%), from 5 of 5 weeksJan 2025: average weekly share 5% (left 2%, center 3%, right 1%), from 4 of 4 weeksFeb 2025: average weekly share 2% (left 1%, center 1%, right under 1%), from 4 of 4 weeksMar 2025: average weekly share 0% (left 0%, center 0%, right 0%), from 5 of 5 weeksApr 2025: average weekly share 0% (left 0%, center 0%, right 0%), from 4 of 4 weeksMay 2025: average weekly share 0% (left 0%, center 0%, right 0%), from 4 of 4 weeksJun 2025: average weekly share 0% (left 0%, center 0%, right 0%), from 5 of 5 weeksJul 2025: average weekly share 0% (left 0%, center 0%, right 0%), from 4 of 4 weeksAug 2025: average weekly share 0% (left 0%, center 0%, right 0%), from 4 of 4 weeksSep 2025: average weekly share 6% (left 2%, center 3%, right 1%), from 5 of 5 weeksOct 2025: average weekly share 0% (left 0%, center 0%, right 0%), from 4 of 4 weeksNov 2025: average weekly share 0% (left 0%, center 0%, right 0%), from 4 of 4 weeksDec 2025: average weekly share 0% (left 0%, center 0%, right 0%), from 5 of 5 weeksJan 2026: average weekly share 1% (left 1%, center under 1%, right under 1%), from 4 of 4 weeksFeb 2026: average weekly share 1% (left under 1%, center under 1%, right 0%), from 4 of 4 weeksMar 2026: average weekly share 1% (left 0%, center 0%, right 1%), from 5 of 5 weeksApr 2026: average weekly share 5% (left 2%, center 1%, right 1%), from 4 of 4 weeksMay 2026: average weekly share 13% (left 5%, center 5%, right 2%), from 4 of 4 weeksJun 2026: average weekly share 0% (left 0%, center 0%, right 0%), from 5 of 5 weeksJul 2026: average weekly share 0% (left 0%, center 0%, right 0%), from 4 of 4 weeksAug 2026: average weekly share under 1% (left under 1%, center 0%, right under 1%), from 5 of 5 weeksSep 2026: average weekly share 1% (left under 1%, center under 1%, right under 1%), from 4 of 4 weeksOct 2026: average weekly share 1% (left under 1%, center under 1%, right under 1%), from 4 of 4 weeksNov 2026: average weekly share 0% (left 0%, center 0%, right 0%), from 2 of 2 weeks, so far

LeftCenterRight

Each bar is the share of the outlets on our Left / Center / Right rating scale that we tracked publishing that week which carried reporting on this story, split by the outlets' ratings. Over more than two years each bar is a month: the average of that month's weekly shares, so the shape stays readable. The weekly table below keeps every week. We track more outlets now than in the archive, so a share keeps earlier and later weeks comparable. An outlet counts once a week however much it published, and outlets in one ownership or syndication group count as one on each side they appear on. A rating describes the outlet, not the report. A gap means no such reports were collected that week, not that nothing was reported anywhere. Weeks run Monday to Sunday in UTC, so a report published on a Sunday evening in US Eastern time counts in the next week. 14 more outlets off the scale (not rated, or outside the left-right graphs) also reported; they are not in this chart. See them.

Weekly counts, outlets and reports (45 weeks with coverage)
Outlets on the rating scale that carried this story each week, of the outlets tracked that week, newest first
Week of (UTC)LeftCenterRightOf trackedShareReceipts
Oct 5, 202679420 of 4794%
Sep 28, 202689724 of 4765%
Aug 10, 20263025 of 5451%
May 11, 20262023952 of 17630%
May 4, 20261814840 of 17523%
Apr 27, 2026129829 of 16018%
Mar 9, 20260066 of 1664%
Feb 2, 20262204 of 1772%
Jan 12, 20264217 of 1914%
Sep 29, 202511211042 of 20221%
Sep 1, 202579218 of 17710%
Feb 10, 202549114 of 2147%
Feb 3, 20252226 of 1903%
Jan 27, 202588521 of 2239%
Jan 13, 2025615324 of 22811%
Dec 16, 20240123 of 2261%
Dec 9, 20241112427 of 20813%
Nov 4, 202432510 of 2234%
Sep 30, 202427110 of 2225%
Jun 10, 2024454419108 of 24744%
May 20, 202413211246 of 22620%
May 13, 202448517 of 2168%
Apr 29, 20240538 of 2373%
Mar 25, 202432451390 of 24537%
Mar 18, 202466416 of 2467%
Feb 26, 20241816640 of 25616%
Feb 5, 20241517 of 2423%
Jan 29, 20242147 of 2353%
Dec 11, 202325292175 of 22533%
Sep 4, 202369419 of 2538%
Aug 21, 20231348 of 2433%
Aug 14, 202314171243 of 24617%
May 8, 202325310 of 2544%
Apr 24, 20233508 of 2553%
Apr 17, 2023454922116 of 25446%
Apr 10, 2023494422115 of 25445%
Apr 3, 202331371785 of 26033%
Mar 13, 20231824749 of 18327%
Mar 6, 20230101 of 1771%
Feb 6, 2023618731 of 18517%
Jan 2, 202322251966 of 19135%
Nov 14, 20222158 of 1864%
Feb 21, 20222608 of 2004%
Dec 13, 202111201041 of 19521%
Nov 29, 20211304 of 2182%

Latest coverage

The newest reporting in this story's record.

  1. Oct 7, 2026 · first reported · Headline from WHEC Rochester

    FDA says its safety review of abortion pill will continue into next year

Background

In December 2021, the Food and Drug Administration permanently dropped its requirement that mifepristone be picked up in person,[9] the same month a Texas law limiting access to abortion pills took effect.[10] In January 2023 the FDA finalized a rule letting certified retail and mail-order pharmacies dispense the drug.[11][12] By then anti-abortion groups had sued to reverse the FDA's approval of mifepristone, first granted in 2000.[13][14] On April 7, 2023, a federal judge in Texas ruled the approval improper, while a federal judge in Washington state ordered the FDA to keep the drug available in 17 states.[15][16] The Justice Department appealed,[17] an appeals court kept the pill available with restrictions,[18] and the Supreme Court froze the lower-court rulings while the case continued.[19]

Read the full background (3 more paragraphs)

The case, brought by the Alliance for Hippocratic Medicine, reached the Supreme Court after the Fifth Circuit appeals court ruled to restrict the drug in August 2023.[20][21] Before the argument, a publisher retracted studies the Texas judge had relied on.[22] On June 13, 2024, the court unanimously rejected the challenge, ruling that the anti-abortion doctors who brought it lacked standing to sue.[3] Walgreens and CVS began selling the drug in some states,[23] and a survey found that about 8,000 women a month were getting abortion pills despite their states' bans or restrictions, often through telehealth.[24] Louisiana became the first state to classify mifepristone and misoprostol as controlled dangerous substances.[25][26]

With Donald Trump's return, the fight moved to doctors who prescribe the pills across state lines under shield laws meant to protect them. Texas Attorney General Ken Paxton sued a New York doctor for mailing pills to Texas,[27] and a Texas judge fined her more than $100,000;[28] a Louisiana a New York doctor, Margaret Carpenter, on charges of prescribing pills to a pregnant minor, and New York Gov. Kathy Hochul signed a law to shield prescribers' identities.[5][29] Texas passed a law letting residents sue out-of-state pill providers,[30] and a California doctor became the first sued under it.[6] Gov. Gavin Newsom refused Louisiana's request to extradite a California doctor it had charged with mailing pills.[31][32] Meanwhile three states pressed a new suit before the same Texas judge,[33] the FDA approved a new generic version of the drug, angering conservatives,[34] and Republican Sen. Josh Hawley introduced a bill to withdraw its approval.[35]

In May 2026 an appeals court temporarily blocked the federal rule allowing mifepristone to be dispensed by mail,[36] and after a short stay signed by Justice Samuel Alito, the Supreme Court kept telemedicine and mail access in place.[37][4] Anti-abortion groups then urged Attorney General Todd Blanche to stop the mailing of abortion pills,[38] three states with near-total bans asked the Supreme Court to strike down shield laws,[7] and the FDA said its safety review of the drug would run into next year, a timeline abortion opponents quickly condemned.[8]

Supporting stories (38)
  1. What is mifepristone, the drug at the heart of the Texas medication abortion lawsuit?
  2. Court schedules abortion pill case for March argument session
  3. Supreme Court upholds broad access to key abortion pill Mifepristone
  4. Supreme Court preserves access to widely used abortion pill, while lawsuit plays out
  5. New York doctor indicted for prescribing abortion pill in Louisiana
  6. California doctor sued for allegedly providing abortion pill to Texas patient
  7. Republican AGs sue abortion ‘shield law’ states in US Supreme Court
  8. FDA says its safety review of abortion pill will continue into next year
  9. Abortion pills by mail to be allowed as US health regulators permanently loosen restrictions
  10. As Roe hangs in the balance, new Texas law restricts use of abortion-inducing medicine
  11. FDA to allow pharmacies to dispense abortion pills to patients
  12. Now able to sell abortion pill, U.S. pharmacies weigh if they should
  13. Conservative group sues FDA to revoke approval of abortion pill
  14. Texas Lawsuit Could Pull Abortion Pill Off the Market Nationwide
  15. US appeals court preserves access to abortion pill but tightens rules
  16. Judge in Washington orders feds to keep abortion pill access, countering ruling by Texas judge
  17. Justice Department appeals Texas court ruling to halt order of commonly used abortion pill
  18. Abortion opponents urge Supreme Court to allow limits on abortion drug
  19. Supreme Court Preserves Access to Abortion Pill, for Now: What's Next?
  20. Appeals court wants limits on abortion pill access, sending case to Supreme Court
  21. Justice Department asks Supreme Court to end abortion pill legal challenge that threatens widespread access
  22. Studies cited in case over abortion pill are retracted due to flaws and conflicts of interest
  23. Walgreens, CVS to start selling abortion pill in store
  24. Survey finds 8,000 women a month got abortion pills despite their states' bans or restrictions
  25. Louisiana governor signs bill to classify abortion pills as controlled substances into law
  26. A new Louisiana law requires abortion meds to be locked in a cabinet, even if needed for emergency care
  27. Ken Paxton sues New York doctor accused of prescribing abortion pills to Texas woman
  28. Texas judge fines New York doctor for prescribing abortion pills to a woman near Dallas
  29. New York adds protections for doctors who send abortion pills out of state
  30. Texas lawmakers approve letting private citizens sue abortion pill providers
  31. Louisiana seeks arrest of California doctor accused of mailing abortion pills
  32. Newsom moves to stop Louisiana from extraditing doctor accused of mailing abortion pills
  33. Texas judge says states can revive challenge to abortion pill access nationwide
  34. FDA approves another generic abortion pill, prompting outrage from conservatives
  35. Hawley rolls out bill to nix FDA approval for mifepristone, used for almost two-thirds of US abortions
  36. Federal appeals court restricts abortion access by temporarily blocking the mailing of mifepristone
  37. Supreme Court restores access to abortion pill mifepristone through telehealth, mail and pharmacies
  38. Anti-abortion groups urge AG to halt mailing of abortion pills

The full record

Each date is when an update was first reported.

All 61 recorded updates

October 2026

  1. FDA says its safety review of abortion pill will continue into next yearHeadline from Bangor Daily News · 20 outlets

September 2026

  1. Republican AGs sue abortion ‘shield law’ states in US Supreme CourtHeadline from Billings Gazette · 24 outlets

August 2026

  1. Anti-abortion groups urge AG to halt mailing of abortion pillsHeadline from Kokomo Tribune · 5 outlets

May 2026

  1. Supreme Court temporarily extends women’s access to a widely used abortion pillHeadline from Anchorage Daily News · 20 outlets
  2. Supreme Court preserves access to widely used abortion pill, while lawsuit plays outHeadline from The Boston Globe · 48 outlets

February 2026

  1. California doctor sued for allegedly providing abortion pill to Texas patientHeadline from NBC Los Angeles · 4 outlets

October 2025

  1. FDA approves another generic abortion pill, prompting outrage from conservativesHeadline from Minneapolis Star Tribune · 38 outlets

January 2025

  1. New York doctor indicted for prescribing abortion pill in LouisianaHeadline from CBS News · 24 outlets
  2. Texas judge says states can revive challenge to abortion pill access nationwideHeadline from NBC4 Washington · 25 outlets

December 2024

  1. Ken Paxton sues New York doctor accused of prescribing abortion pills to Texas womanHeadline from Fox26 Houston · 29 outlets

November 2024

  1. Anti-abortion advocates press Trump for more restrictions as abortion pill sales spikeHeadline from Winchester Star · 9 outlets

June 2024

  1. Supreme Court upholds broad access to key abortion pill MifepristoneHeadline from New Hampshire Union Leader · 113 outlets

Coverage & sources

Read the reports, see how much was collected over time, or compare outlets by political leaning.

Coverage & sources →